175 related articles for article (PubMed ID: 37038139)
21. Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer.
Chiappetta C; Anile M; Leopizzi M; Venuta F; Della Rocca C
Clin Chim Acta; 2013 Oct; 425():93-6. PubMed ID: 23892142
[TBL] [Abstract][Full Text] [Related]
22. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
Yang X; Zhang K; Zhang C; Peng R; Sun C
BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
[TBL] [Abstract][Full Text] [Related]
23. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
[TBL] [Abstract][Full Text] [Related]
24. Development of a multiplex methylation specific PCR suitable for (early) detection of non-small cell lung cancer.
Nawaz I; Qiu X; Wu H; Li Y; Fan Y; Hu LF; Zhou Q; Ernberg I
Epigenetics; 2014 Aug; 9(8):1138-48. PubMed ID: 24937636
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
Hyun MH; Lee ES; Eo JS; Kim S; Kang EJ; Sung JS; Choi YJ; Park KH; Shin SW; Lee SY; Kim YH
Lung Cancer; 2019 Aug; 134():158-166. PubMed ID: 31319975
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
27. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
[TBL] [Abstract][Full Text] [Related]
28. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
30. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer.
Xie Y; Zhang Y; Du L; Jiang X; Yan S; Duan W; Li J; Zhan Y; Wang L; Zhang S; Li S; Wang L; Xu S; Wang C
Mol Oncol; 2018 May; 12(5):648-658. PubMed ID: 29504701
[TBL] [Abstract][Full Text] [Related]
31. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
Samulin Erdem J; Skaug V; Bakke P; Gulsvik A; Haugen A; Zienolddiny S
BMC Cancer; 2016 Jan; 16():28. PubMed ID: 26780934
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.
Liu S; Chen X; Chen R; Wang J; Zhu G; Jiang J; Wang H; Duan S; Huang J
Oncotarget; 2017 May; 8(22):36354-36367. PubMed ID: 28422739
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Diagnostic Potential of Candidate Hypermethylated Genes in Epithelial Ovarian Cancer in North Indian Population.
Singh A; Gupta S; Sachan M
Front Mol Biosci; 2021; 8():719056. PubMed ID: 34778370
[TBL] [Abstract][Full Text] [Related]
34. HOXA9 inhibits migration of lung cancer cells and its hypermethylation is associated with recurrence in non-small cell lung cancer.
Hwang JA; Lee BB; Kim Y; Hong SH; Kim YH; Han J; Shim YM; Yoon CY; Lee YS; Kim DH
Mol Carcinog; 2015 Jun; 54 Suppl 1():E72-80. PubMed ID: 24817037
[TBL] [Abstract][Full Text] [Related]
35. The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.
Shen Z; Chen C; Sun J; Huang J; Liu S
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2239-2248. PubMed ID: 34037837
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
[TBL] [Abstract][Full Text] [Related]
37. 5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer.
Zhang J; Han X; Gao C; Xing Y; Qi Z; Liu R; Wang Y; Zhang X; Yang YG; Li X; Sun B; Tian X
Genomics Proteomics Bioinformatics; 2018 Jun; 16(3):187-199. PubMed ID: 30010036
[TBL] [Abstract][Full Text] [Related]
38. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
39. Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients.
Hwang SH; Kim KU; Kim JE; Kim HH; Lee MK; Lee CH; Lee SY; Oh T; An S
Clin Chem Lab Med; 2011 Apr; 49(4):699-704. PubMed ID: 21480815
[TBL] [Abstract][Full Text] [Related]
40. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer.
Chen N; Li G; Li H; Xiang X; Guo G; Ma Q; Zhang Y
Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):208-213. PubMed ID: 33040838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
